RCUS
Arcus Biosciences, Inc.
$18.54
-4.24%
2026-10-23
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Key Fundamentals
Forward P/E
-7.38
EPS (TTM)
$-3.94
ROE
-90.8%
Revenue Growth (YoY)
-74.4%
Profit Margin
0.0%
Debt/Equity
51.29
Price/Book
6.83
Beta
0.81
Market Cap
$3.18B
Avg Volume (10D)
2.1M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$31.58
60D Low
$17.43
Avg Volume
1.8M
Latest Close
$18.54
Get breakout alerts for RCUS
Sign up for Breakout Scanner to receive daily notifications when RCUS triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Arcus Biosciences, Inc. (RCUS) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors RCUS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. RCUS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.